Objective To investigate the effect of recombinant interleukin-2( r IL-2) combined with allicin in the treatment of pancreatic cancer and related mechanisms. Methods A nude mouse xenograft model was established. A total of 60 nude mice were randomized into control group,r IL-2 treatment group,allicin treatment group,and combined treatment group. At 4 weeks after treatment,peripheral blood was collected,tumor volume,tumor weight,and survival time were recorded,and survival rates were calculated. Flow cytometry was used to analyze the apoptosis of tumor cells and measure the percentages of CD4+T,CD8+T,and natural killer( NK) cells,ELISA was used to measure the level of interferonγ( IFNγ),and Western blot was used to measure the expression of Bcl-2 protein in tumor tissue. An analysis of variance was used for comparison of continuous data between groups,and SNK-q test was used for further comparison between any two groups. Results At 4 weeks after treatment,the r IL-2 treatment group,allicin treatment group,and combined treatment group showed significant reductions in tumor volume compared with the control group( all P < 0. 05),and the combined treatment group showed the greatest reduction( P < 0. 01). The combined treatment group had a tumor inhibition rate of 90. 5% and a prolonged survival time( 60% of the mice survived at 55 days). Compared with the control group,the combined treatment group showed significant increases in the apoptosis rate of tumor cells( 23. 3% ± 4. 3% vs 9. 0% ± 3. 7%,P < 0. 05) and the expression of pro-apoptotic protein Bcl-2. The treatment groups showed significant increases in the percentages of CD4+T,CD8+T,and NK cells compared with the control group( F = 23. 74,26. 38,and 19. 72,all P < 0. 001). Compared with the other three groups,the combined treatment group showed a significant increase in the IFNγlevel( F = 9. 84,P = 0. 026). Conclusion Combined treatment with allicin and r IL-2 can enhance the innate immunity and adaptive immunity and thus improve the survival of pancreatic cancer.
[1]HARIHARAN D,SAIED A,KOCHER HM.Analysis of mortality rates for pancreatic cancer across the world[J].HPB(Oxford),2008,10(1):58-62.
|
[2]LIU J,ZHANG S,HU Y,et al.Targeting PD-1 and TIM-3pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic/tumor vaccines[J].J Immunother,2016,39(4):171-180.
|
[3]BORREGALES LD,ADIBI M,THOMAS AZ,et al.The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma[J].Ther Adv Urol,2016,8(2):130-141.
|
[4]JIN JF,ZHU LL,CHEN M,et al.The optimal choice of medication administration route regarding intravenous,intramuscular,and subcutaneous injection[J].Patient Prefer Adherence,2015,9:923-942.
|
[5]WANG CJ,WANG C,HAN J,et al.Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer[J].Mol Biol Rep,2013,40(12):6579-6585.
|
[6]WANG ZH,CHEN H,GUO HC,et al.Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of xiap in vitro and in vivo[J].Int J Oncol,2011,39(5):1123-1131.
|
[7]SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
|
[8]KOIDO S,HOMMA S,OKAMOTO M,et al.Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions[J].Oncoimmunology,2013,2(9):e25994.
|
[9]ADEWALE OO,BRIMSON JM,ODUNOLA OA,et al.The potential for plant derivatives against acrylamide neurotoxicity[J].Phytotherapy Res,2015,29(7):978-985.
|
[10]BHANDARI P.Dietary botanicals for chemoprevention of prostate cancer[J].J Tradit Complement Med,2014,4(2):75-76.
|
[11]SPROUSE AA,STEDING CE,HERBERT BS.Pharmaceutical regulation of telomerase and its clinical potential[J].J Cell Mol Med,2012,16(1):1-7.
|
[12]BALLAS ZK,BUCHTA CM,ROSEAN TR,et al.Role of NK cell subsets in organ-specific murine melanoma metastasis[J].PLo S One,2013,8(6):e65599.
|
[13]JIANG W,HUANG Y,WANG JP,et al.The synergistic anticancer effect of artesunate combined with allicin in osteosarcoma cell line in vitro and in vivo[J].Asian Pac J Cancer Prev,2013,14(8):4615-4619.
|
[14]FUJII S,SHIMIZU K,OKAMOTO Y,et al.Nkt cells as an ideal anti-tumor immunotherapeutic[J].Front Immunol,2013,4:409.
|
1. | 周猛,梁园园,曲晨菲,翟艺,张涛,亓文倩,张竞竞,岳启安. 多价葡萄球菌菌苗对小鼠IL-2R、TNF-αR基因表达及血清IL-2水平的影响. 中国现代医药杂志. 2019(09): 6-9 . ![]() | |
2. | 程海峰,赵振民,杨庆民,平玉杰,丁瑞,文红壮,李博科,王磊. 冷冻消融联合索拉非尼和IL-2治疗裸鼠肾癌移植瘤的实验研究. 河北医药. 2018(11): 1630-1633 . ![]() | |
3. | 石国建,顾蓓,荣鸣,李惠华. 大蒜素辅治乳腺癌及对小鼠血清CA153、CEA及免疫功能的影响. 湖南师范大学学报(医学版). 2018(06): 100-103 . ![]() | |
4. | 金添强,徐锋,戴朝六. 胰腺癌肝转移免疫治疗的研究进展. 临床肝胆病杂志. 2018(11): 2469-2474 . ![]() | |
5. | 肖林峰,李文岗. 异位胰腺诊治进展. 中外医疗. 2016(36): 196-198 . ![]() |